A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : APR / aprepitant

[Related PubMed/MEDLINE]
Total Number of Papers: 19
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   APR  (>> Co-occurring Abbreviation)
Long Form:   aprepitant
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. FosAPR, ICER, QALYs
2018 A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). CINV, CR, DEX, GRAN, HEC
2017 Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. CINV, fAPR, HEC, MEC, NEPA, NHS, Onda, PALO, QALY
2017 Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study. CP, CR, DEX, PALO
2016 Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. CR, DEX, NK1RA, NK1RA, PALO
2016 Hot melt extruded Aprepitant-Soluplus solid dispersion: preformulation considerations, stability and in vitro study. DSC, DVS, FaSSIF, GFA, GS, HME, SOL
2016 Omission of dexamethasone from antiemetic treatment for highly emetogenic chemotherapy in breast cancer patients with hepatitis B infection or diabetes mellitus. CC, CR, DM, GRA, HBV, PAL
2016 The effect of aprepitant and dexamethasone combination on paclitaxel-induced hypersensitivity reaction. DEX, HSR, PTX
2016 The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India. CINV, CR, HEC, OLN
10  2015 [Appropriate dosing of fosaprepitant for colon cancer patients]. FOS
11  2014 A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. AEs, CR, DEX, PALO, RA
12  2014 Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. CINV, CR, NETU, NK-1, OND, PALO, RA
13  2014 Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-beta-cyclodextrin complex. SBE-beta-CD
14  2013 Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant. BEP, EPI/CPA, HEC
15  2013 Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. CINV, PONV
16  2012 [Antiemetic effect of aprepitant in cancer patients receiving Cisplatin regimen]. CDDP
17  2011 Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. APD, CINV, CR, DEX, OLN, OPD, PAL
18  2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. CR, DEX, MEC, OND
19  2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. CINV, OND